Leukocyte reduction in blood component supply: The impact of flow cytometry in assessing residual leukocytes

Transfusion Medicine and Hemotherapy

Volumn 32, Issue 1, 2005, Pages 12-19

  Schlenke, Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cost effectiveness; Flow cytometry; Leukocyte enumeration; Platelet concentrates; Quality control; Red blood cell units; Residual leukocyte

Indexed keywords

ALLOGRAFT; ALLOIMMUNIZATION; BLOOD COMPONENT; CREUTZFELDT JAKOB DISEASE; DECISION MAKING; DISEASE ASSOCIATION; FLOW CYTOMETRY; GERMANY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; PHENOTYPE; REVIEW; UNITED KINGDOM;

EID: 24044471002     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082125     Document Type: Review

References (32)

1. Heddle NM, Klama L, Meyer R, Walker I, Boshkov L, Roberts R, Chambers S, Podlosky L, O'Hoski P, Levine M: A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999;39:231-238.
2. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B, irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
3. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV-infection after marrow transplant. Blood 1995;86:3598-3603.
4. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M: Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101:4195-4200.
5. Vamvakas EC, Blajchmann MA: Universal WBC reduction: The case for and against. Transfusion 2001;41:691-712.
6. Guide to the Preparation, Use and Quality Assurance of Blood Components, 10th ed. Strasbourg, Council of Europe, 2004.
7. Dumont DJ, Dzik WH, Rebulla P, Brandwein H: Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfusion 1996;36:11-20.
8. Zoon KG: Recommendations and licensure requirements for WBC-reduced blood products. Bethesda, Federal Drug Administration, May 1996. www.fda.gov/cber/ bldmem/mem52996.txt.
9. Dzik S, Moroff G, Dumont L, for the Biomedical Excellence for Safer Transfusion (BEST) working party of the ISBT: A multicenter study evaluating three methods for counting residual WBCs in WBC-reduced blood components: Nageotte hemocytometry, flow cytometry, and microfluorimetry. Transfusion 2000;40:513-520.
10. Dijkstra-Tiekstra MJ, Schrijver JG, van der Meer PF, Laport RF, Gratama JW, Levering WH, van Delden CJ, de Wildt-Eggen J: Crossover study of three methods for low-level white blood cell counting on two types of flow cytometer. Cytometry 2003;54B:39-45.
11. Arndt PA, Garratty G: Flow cytofluorometric analysis in red blood cell immunology. Transfus Med Hemother 2004;31:163-174.
12. Backteman K, Ledent E, Berlin G, Ernerudh J: A rapid and reliable flow cytometric routine method for counting leukocytes in leukocyte-depleted platelet concentrates. Vox Sang 2002;83:29-34.
13. Adams MR, Fisher DM Dumont LJ, Dzik WH, Heaton WA: Detecting failed WBC-reduction processes: Computer simulations of intermittent and continuous process failure. Transfusion 2000;40:1427-1433.
14. Jensen LS, Kissmeyer-Nielsen P, Wolff B: Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348: 841-845.
15. Van de Watering LMG, Hermans J, Houbiers JGA, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A: Beneficial effects of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation 1998;97:562-568.
16. Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kaish LA, Stowell CP: A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42:1114-1122.
17. Williamson LM, Murphy MF, Llewelyn C, Todd A, Taylor R, Stevens W: Leukocyte-depleted blood in prevention of post-operative infections following elective orthopaedic and cardiac procedures. Vox Sang 2002;83(suppl 1):457-460.
18. MacGregor IR, Prowse CV: Impacts and concerns for vJCD in blood transfusion: Current status. Curr Mol Med 2004;4:361-373.
19. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie RG: Possible transmission of variant Creutzfeldt-Jakob disease by transfusion. Lancet 2004;363:417-421.
20. Dzik WH: Leukocyte counting during process control of leukoreduced blood components. Vox Sang 2000;78(suppl 2):223-226.
21. Barnett D, Goodfellow K, Ginnever J, Granger V, Whitby L, Reilly JT: Low level leukocyte counting: A critical variable in the validation of leukodepleted blood transfusion components as highlighted by an external quality assessment study. Clin Lab Haematol 2001;23:43-51.
22. Lee TH, Stromberg RR, Heitman J, Tran K, Busch MP: Quantitation of residual leukocytes in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA. Transfusion 1994;34:986-994.
23. Gerstner A, Laffers W, Bootz F, Tarnok A: Immunophenotyping of peripheral blood leukocytes by laser scanning cytometry. J Immunol Meth 2000;246:175-185.
24. Cardigan R, Phipps A, Seghatchian J, Bashir S, Aynsley S, Beckman N, Barnett D, Reilly JT, Williamson LM: The development of a national standardized approach for the enumeration of residual leukocytes in blood components. Vox Sang 2002;83:100-109.
25. Beckman N, Cardigan R, Wallington T, Williamson LM: Value of central analysis of leukocyte depletion quality control data within the National Blood Service, England. Vox Sang 2002;83:110-118.
26. Goodfellow KJ, Storie I, Granger V, Whitby L, Antcliffe J, Reilly JT, Barnett D: The United Kingdom National External Quality Assessment Scheme gating and standardization strategy for use in residual WBC counting of WBC-reduced blood components. Transfusion 2002;42:738-746.
27. Bontadini A, Tazzari PL, Manfroi S, Tassi C, Conte R: Apoptosis in leucodepleted packed red blood cells. Vox Sang 2002;83:35-41.
28. NCCLS: Preliminary Evaluation of Quantitative Clinical Laboratory Methods; Approved Guideline, 2nd ed. NCCLS document EP10-A2, USA, 2002, ISBN 1-56238-482-1
29. ICH Topic Q 2 B: Note for Guidance on Validation of Analytical Procedures: Methodology (CPMP/ ICH/281/95), UK, 1997.
30. Krailadsiri P, Seghatchian J: Residual red cell and platelet content in WBC-reduced plasma measured by a novel flow cytometric method. Transfus Apheresis Sci 2001;24:279-286.
31. Jilma-Stohlawetz P, Marsik C, Horvath M, Siegmeth H, Höcker P, Jilma B: A new flow cytometric method for simultaneous measurement of residual platelets and RBCs in plasma: Validation and application for QC. Transfusion 2001;41:87-92.
32. Pichler J, Printz D, Scharner D, Trbojevic D, Siekmann J, Fritsch G: Improved flow cytometric method to enumerate residual cells with minimal linear detection limits for platelets, erythrocytes, and leukocytes. Cytometry 2002;50:231-237.